Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma

CONCLUSIONS: ICI administration at RFD can allow extension of treatment duration, while preserving efficacy and reducing logistical and financial burden. RFD approach deserves further exploration in prospective clinical trials.PMID:37733060 | DOI:10.1007/s00262-023-03539-8

Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Lisa May Ling Tachiki Daniel S Hippe Karly Williams Silva Evan Thomas Hall William McCamy Dane Fritzsche Andrea Perdue Julia Majovski Thomas Pulliam Daniel A Goldstein Joshua Veatch Joel Ho Paul T Nghiem John A Thompson Shailender Bhatia Source Type: research